SEC Form 6-K Summary
Business Context and Reporting Period
Medirom Healthcare Technologies Inc. filed a Form 6-K for March 2023, dated March 16, 2023. The filing reports developments concerning the continued listing of the Company’s American Depositary Shares on Nasdaq. It does not provide operating or financial results for the period.
Key Financial Metrics and Liquidity
The filing does not provide clear values for revenue, profit, cash flow, margins, debt, cash balances, liquidity, or other operating metrics. Nasdaq’s continued-listing condition references a minimum net income from continuing operations of $500,000 under Nasdaq Listing Rule 5550(b)(3), measured in the most recently completed fiscal year or two of the last three most recently completed fiscal years.
Material Changes Versus the Prior Comparable Period
- On December 28, 2022, the Company received notice that its ADSs were subject to suspension and delisting because it did not meet Nasdaq’s $35 million market value of listed securities requirement under Rule 5550(b)(2), based on the measurement date of December 27, 2022.
- The Company appealed and attended a Nasdaq Hearings Panel hearing on February 16, 2023.
- On March 15, 2023, the Panel granted continued listing through May 1, 2023, subject to the Company evidencing compliance with the net income standard under Rule 5550(b)(3).
Guidance, Outlook, Risks, and Unusual Items
The Company intends to file its Annual Report on Form 20-F for the year ended December 31, 2022 by April 30, 2023. If it cannot demonstrate compliance with the net income requirement by May 1, 2023, it intends to notify the Panel and submit an updated compliance plan. Nasdaq would then reassess the Company’s continued listing.
Key risks include failure to timely file the Form 20-F, failure to demonstrate compliance with the applicable Nasdaq listing requirement, and the possibility that Nasdaq will not ultimately grant relief from delisting. The filing also identifies forward-looking statements regarding the Company’s expectation that it will meet the net income standard, while cautioning that actual results and event timing may differ materially.
The Company issued a March 16, 2023 press release, furnished as Exhibit 99.1. The press release is not deemed filed for purposes of Section 18 of the Securities Exchange Act.
Important Facts for Investors to Verify
- Whether the Company filed its fiscal-year 2022 Form 20-F by April 30, 2023.
- Whether fiscal-year 2022 results demonstrated at least $500,000 of net income from continuing operations, or otherwise satisfied the applicable Nasdaq standard.
- Whether Nasdaq ultimately maintained or terminated the Company’s listing after May 1, 2023.
- The Company’s fiscal-year 2022 revenue, profitability, cash flow, cash balance, debt, and liquidity, which are not provided in this Form 6-K.